Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 120 for your search:
Cancer Type:
Breast cancer, female
Stage/Subtype of Cancer:
stage I breast cancer
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Aromatase Inhibitor Clinical Trial
Phase:
Phase IV
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
40 to 70
Sponsor:
NIGMS
Protocol IDs:
0412-14
, UO1-GM61373-06, NCT00228956
2.
Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer
Phase:
Phase IV
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 45
Sponsor:
Other
Protocol IDs:
0501-37
, NCT00352872
3.
Using the Conture® Multi-Lumen Balloon to Deliver Accelerated Partial Breast Brachytherapy
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
50 and over
Sponsor:
Other
Protocol IDs:
SENORX-S07-002
, NCT00699101
4.
Clinical and Histologic Evaluation of Acellular Dermal Matrix Substitute in Breast Reconstruction
Phase:
Phase IV
Type:
Supportive care, Treatment
Status:
Active
Age:
18 to 80
Sponsor:
Other
Protocol IDs:
26658
, NCT00872859
5.
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
Phase:
Phase III, Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 85
Sponsor:
Other
Protocol IDs:
20050113
, NCT00243685
6.
Letrozole After Tamoxifen in Treating Women With Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Postmenopausal
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
CAN-NCIC-MA17
, CALGB-49805, E-JMA17, EORTC-10983, IBCSG-BIG97-01, NCCTG-JMA17, SWOG-JMA17, JRF-Vor-Int-10, NCCTG-CAN-MA17, SWOG-CAN-MA17, NCT00003140, JMA17, MA17
7.
Combination Chemotherapy in Treating Women With Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CALGB-40101
, NCT00041119
8.
Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Premenopausal
Sponsor:
NCI
Protocol IDs:
IBCSG-2402
, BIG-2-02, CALGB-IBCSG-2402, CAN-NCIC-IBCSG-2402, NCCTG-IBCSG-2402, NSABP-IBCSG-2402, SWOG-IBCSG-2402, NABCI-IBCSG-2402, UCLA-0403024-01, EU-20334, IBCSG-24-02, NCT00066690, EUDRACT-2004-000166-13
9.
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Premenopausal
Sponsor:
NCI
Protocol IDs:
IBCSG-25-02
, BIG-3-02, NABCI-IBCSG-25-02, EU-20347, NCT00066703, EUDRACT-2004-000168-28
10.
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
SWOG-S0221
, S0221, NCT00070564
11.
Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
IBCSG-27-02
, BIG-1-02, EU-20320, NCT00074152, NSABP-B-37, EUDRACT-2005-001484-64
12.
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NSABP-B-39
, RTOG-0413, SWOG-NSABP-B-39, NCT00103181
13.
Zoledronate, Clodronate, or Ibandronate in Treating Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
SWOG-S0307
, NCCTG-SWOG-S0307, ECOG-SWOG-S0307, NSABP-SWOG-S0307, CALGB-SWOG-S0307, CAN-NCIC-SWOG-S0307, S0307, NCT00127205
14.
Nexium Study To Suppress Nausea During Chemotherapy
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
H-16348
, Nexium Study, NCT00206440
15.
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
ECOG-PACCT-1
, SWOG-ECOG-PACCT-1, CALGB-ECOG-PACCT-1, NCCTG-ECOG-PACCT-1, NSABP-ECOG-PACCT-1, ACOSOG-ECOG-PACCT-1, CAN-NCIC-MAC12, PACCT-1, NCT00310180, TAILORx
16.
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Any age (postmenopausal)
Sponsor:
NCI
Protocol IDs:
NSABP-B-42
, NCT00382070
17.
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NSABP-B-40
, NCT00408408
18.
Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ECOG-E5103
, E5103, NCT00433511
19.
Regional Anesthesia and Breast Cancer Recurrence
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 85
Sponsor:
Other
Protocol IDs:
06-692
, NCT00418457
20.
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A6181114
, NCT00428220
21.
Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
15 to 46
Sponsor:
Other
Protocol IDs:
2005-0464
, NCT00429403
22.
Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer
Phase:
Phase III
Type:
Behavioral study, Supportive care, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
OCOG-2007-LISA
, NCT00463489
23.
ALTTO(Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation)Study; BIG 2-06/N063D
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
EGF106708
, BIG 2-06/N063D/MAC13, NCT00490139
24.
TAC Versus TC for Adjuvant Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
Other
Protocol IDs:
11271
, NCT00493870
25.
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ACOSOG-Z1041
, Z1041, NCT00513292
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
